Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Other Revenues: $2,142M in FY2025, up 52.5% from a year earlier. That is the highest of the 10 years on record here.
Latest, FY2025
2,142
Period ended Dec 31, 2025
Change on a year earlier
+52.5%
1,405 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below
Where the FY2025 figure comes from
“|| Total other revenues | 524 | 405 | 2 142 | 1 405”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K Note 3 & Form 20-F Note 3.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Revenues ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,142 | +52.5% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 1,405 | +15.2% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 1,220 | -2.8% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 1,255 | +5.2% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 1,193 | -3.7% | Novartis Form 20-F (0001370368-24-000004) ↗ |
| FY2020 | Dec 31, 2020 | 1,239 | +5.1% | Novartis Form 20-F/A (0001370368-23-000048) ↗ |
| FY2019 | Dec 31, 2019 | 1,179 | -6.9% | Novartis Form 20-F (0001370368-22-000010) ↗ |
| FY2018 | Dec 31, 2018 | 1,266 | +23.8% | Novartis Form 20-F (0001370368-21-000006) ↗ |
| FY2017 | Dec 31, 2017 | 1,023 | +11.4% | Novartis Form 20-F (0001370368-20-000003) ↗ |
| FY2016 | Dec 31, 2016 | 918 | – | Novartis Form 20-F (0001370368-19-000002) ↗ |
Breakdown
What makes up other Revenues
Cite this data
StockData. (2026). Novartis Other Revenues ($M), annual FY2016–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/collab-other-revenues-total
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.